Ann: Paradigm delivers IND to US FDA for Pivotal OA Program, page-45

I get the feeling at 2.65 the SP is still in bargain territory.

I can see once the green light is given to Phase 3 - we will be known as a "Phase 3 Company" or the like.

This changes the tone and categorisation in the minds of asset managers (and the categorisation within their investment mandates) and puts us firmly on the radars of Insto investors not to mention big Pharma.

Going through the top investor listing in the FY20 annual report, there's a dearth of instos onboard - and I'd say there will be a time in the near future that there'll be a scramble to get stock.

And this time is nearly upon us, and it's game faces on.

I've significantly added to my position at around the 2.30 to 2.50 range, thought I'd add to both my LTH and trading parcels, but every time I sell down my trading parcel I regret it.

With recent FDA knock-back of the competing drug, you can just feel rivals' eyes upon us.

Despite what the current SP says, value-wise we are already a US +1bn Company - the SP just needs to catch-on! A flood of buying to come once we are a Phase 3 company...in 30 days time.